Recognition of O6MeG lesions by MGMT and mismatch repair proficiency may be a prerequisite for low-dose radiation hypersensitivity

Radiation Research

Volumn 172, Issue 4, 2009, Pages 405-413

  Martin, Lynn ^a,b   Marples, Brian ^c   Coffey, Mary ^a   Lawler, Mark ^b   Hollywood, Donal ^a,b   Marignol, Laure ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O METHYLGUANINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS1; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6; TEMOZOLOMIDE; UNCLASSIFIED DRUG; DACARBAZINE; DRUG DERIVATIVE; GUANINE; O (6) METHYLGUANINE; O(6) BENZYLGUANINE; O(6)-BENZYLGUANINE; O-(6)-METHYLGUANINE;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL KILLING; CELL LINE; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; HYPERSENSITIVITY; MISMATCH REPAIR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIVITY; CELL DIVISION; DRUG EFFECT; DRUG RESISTANCE; ENZYME ACTIVATION; METABOLISM; PHENOTYPE; RADIATION EXPOSURE; TUMOR CELL LINE;

CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DACARBAZINE; DNA MISMATCH REPAIR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; G2 PHASE; GUANINE; HUMANS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PHENOTYPE; RADIATION DOSAGE; RADIATION TOLERANCE;

EID: 70350719677     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/RR1717.1     Document Type: Article

References (44)

1. E. Papouli, P. Cejka and J. Jiricny, Dependence of the cytotoxicity of DNA-damaging agents on the mismatch repair status of human cells. Cancer Res. 64, 3391-3394 (2004).
2. V. O'Brien and R. Brown, Signaling cell cycle arrest and cell death through the MMR system. Carcinogenesis 27, 682-692 (2006).
3. J. Y. Wang and W. Edelmann, Mismatch repair proteins as sensors of alkylation DNA damage. Cancer Cell 9, 417-418 (2006).
4. 2 arrest is activated through Chk1 and Chk2. Mol. Biol. Cell 16, 1513-1526 (2005).
5. 2 checkpoint and to resistance to chemotherapeutic DNA-methylating agents. Mol. Cell. Biol. 23, 8306-8315 (2003).
6. 2-M cell cycle checkpoint arrest following ionizing radiation. Cancer Res. 58, 767-778 (1998).
7. M. J. Hickman and L. D. Samson, Apoptotic signaling in response to a single type of DNA lesion, O(6)-methylguanine. Mol. Cell 14, 105-116 (2004).
8. L. S. Li, J. C. Morales, A. Hwang, M. W. Wagner and D. A. Boothman, DNA mismatch repair-dependent activation of c-Abl/p73alpha/GADD45alpha-mediated apoptosis. J. Biol. Chem. 283, 21394-21403 (2008).
9. M. Meyers, A. Hwang, M. W. Wagner and D. A. Boothman, Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ. Mol. Mutagen. 44, 249-264 (2004).
10. P. Karran and M. Bignami, DNA damage tolerance, mismatch repair and genome instability. Bioessays 16, 833-839 (1994).
11. Y. Hirose, M. S. Berger and R. O. Pieper, Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res. 61, 5843-5849 (2001).
12. R. Fishel, Signaling mismatch repair in cancer. Nat. Med. 5, 1239-1241 (1999).
13. B. Marples and S. J. Collis, Low-dose hyper-radiosensitivity: past, present, and future. Int. J. Radiat. Oncol. Biol. Phys. 70, 1310-1318 (2008).
14. M. C. Joiner, B. Marples, P. Lambin, S. C. Short and I. Turesson, Low-dose hypersensitivity: current status and possible mechanisms. Int. J. Radiat. Oncol. Biol. Phys. 49, 379-389 (2001).
15. B. Xu, S. T. Kim, D. S. Lim and M. B. Kastan, Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol. Cell Biol. 22, 1049-1059 (2002).
16. S. A. Krueger, S. J. Collis, M. C. Joiner, G. D. Wilson and B. Marples, Transition in survival from low-dose hyper-radiosensitivity to increased radioresistance is independent of activation of ATM Ser1981 activity. Int. J. Radiat. Oncol. Biol. Phys. 69, 1262-1271 (2007).
17. P. Lambin, E. P. Malaise and M. C. Joiner, Might intrinsic radioresistance of human tumour cells be induced by radiation? Int. J. Radiat. Biol. 69, 279-290 (1996).
18. B. Marples and M. C. Joiner, The response of Chinese hamster V79 cells to low radiation doses: evidence of enhanced sensitivity of the whole cell population. Radiat. Res. 133, 41-51 (1993).
19. J. Renart, J. Reiser and G. R. Stark, Transfer of proteins from gels to diazobenzyloxymethyl-paper and detection with antisera: a method for studying antibody specificity and antigen structure. Proc. Natl. Acad. Sci. USA 76, 3116-3120 (1979).
20. M. Hermisson, A. Klumpp, W. Wick, J. Wischhusen, G. Nagel, W. Roos, B. Kaina and M. Weller, O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J. Neurochem. 96, 766-776 (2006).
21. I. Turesson, R. Bernefors, M. Book, M. Flogegard, I. Hermansson, K. A. Johansson, A. Lindh, S. Sigurdardottir, U. Thunberg and J. Nyman, Normal tissue response to low doses of radiotherapy assessed by molecular markers a study of skin in patients treated for prostate cancer. Acta Oncol. 40, 941-951 (2001).
22. J. Harney, N. Shah, S. Short, F. Daley, N. Groom, G. D. Wilson, M. C. Joiner and M. I. Saunders, The evaluation of low dose hyper-radiosensitivity in normal human skin. Radiother. Oncol. 70, 319-329 (2004).
23. B. G. Wouters and L. D. Skarsgard, The response of a human tumor cell line to low radiation doses: evidence of enhanced sensitivity. Radiat. Res. 138 (Suppl.), S76-S80 (1994).
24. B. G. Wouters, A. M. Sy and L. D. Skarsgard, Low-dose hypersensitivity and increased radioresistance in a panel of human tumor cell lines with different radiosensitivity. Radiat. Res. 146, 399-413 (1996).
25. P. S. Lin and A. Wu, Not all 2 Gray radiation prescriptions are equivalent: Cytotoxic effect depends on delivery sequences of partial fractionated doses. Int. J. Radiat. Oncol. Biol. Phys. 63, 536-544 (2005).
26. L. M. Garcia, J. Leblanc, D. Wilkins and G. P. Raaphorst, Fitting the linear-quadratic model to detailed data sets for different dose ranges. Phys. Med. Biol. 51, 2813-2823 (2006).
27. R. M. Hermann, H. A. Wolff, H. Jarry, P. Thelen, C. Gruendker, M. Rave-Fraenk, H. Schmidberger and H. Christiansen, In vitro studies on the modification of low-dose hyper-radiosensitivity in prostate cancer cells by incubation with genistein and estradiol. Radiat. Oncol. 3, 19 (2008).
28. A. E. Pegg, M. E. Dolan, D. Scicchitano and K. Morimoto, Studies of the repair of O6-alkylguanine and O4-alkylthymine in DNA by alkyltransferases from mammalian cells and bacteria. Environ. Health Perspect. 62, 109-114 (1985).
29. J. Rzeszowska-Wolny, J. Polanska, M. Pietrowska, O. Palyvoda, J. Jaworska, D. Butkiewicz and R. Hancock, Influence of polymorphisms in DNA repair genes XPD, XRCC1 and MGMT on DNA damage induced by gamma radiation and its repair in lymphocytes in vitro. Radiat. Res. 164, 132-140 (2005).
30. M. Debiak, T. Nikolova and B. Kaina, Loss of ATM sensitizes against O6-methylguanine triggered apoptosis, SCEs and chromosomal aberrations. DNA Repair (Amst.) 3, 359-368 (2004).
31. B. Marples, P. Lambin, K. A. Skov and M. C. Joiner, Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells. Int. J. Radiat. Biol. 71, 721-735 (1997).
32. S. A. Krueger, M. C. Joiner, M. Weinfeld, E. Piasentin and B. Marples, Role of apoptosis in low-dose hyper-radiosensitivity. Radiat. Res. 167, 260-267 (2007).
33. 2-phase cells. Radiat. Res. 161, 247-255 (2004).
34. C. L. Bean, C. I. Bradt, R. Hill, T. E. Johnson, M. Stallworth and S. M. Galloway, Chromosome aberrations: persistence of alkylation damage and modulation by O6-alkylguanine-DNA alkyltransferase. Mutat. Res. 307, 67-81 (1994).
35. S. M. Galloway, S. K. Greenwood, R. B. Hill, C. I. Bradt and C. L. Bean, A role for mismatch repair in production of chromosome aberrations by methylating agents in human cells. Mutat. Res. 346, 231-245 (1995).
36. S. C. Short, S. A. Mitchell, P. Boulton, M. Woodcock and M. C. Joiner, The response of human glioma cell lines to low-dose radiation exposure. Int. J. Radiat. Biol. 75, 1341-1348 (1999).
37. S. C. Short, J. Kelly, C. R. Mayes, M. Woodcock and M. C. Joiner, Low-dose hypersensitivity after fractionated low-dose irradiation in vitro. Int. J. Radiat. Biol. 77, 655-664 (2001).
38. S. Chandna, B. S. Dwarakanath, D. Khaitan, T. L. Mathew and V. Jain, Low-dose radiation hypersensitivity in human tumor cell lines: effects of cell-cell contact and nutritional deprivation. Radiat. Res. 157, 516-525 (2002).
39. A. Lorente, W. Mueller, E. Urdangarin, P. Lazcoz, U. Lass, A. von Deimling and J. S. Castresana, RASSF1A, BLU, NORE1A, PTEN and MGMT expression and promoter methylation in gliomas and glioma cell lines and evidence of deregulated expression of de novo DNMTs. Brain Pathol. 19, 279-292 (2009).
40. W. P. Roos, L. F. Batista, S. C. Naumann, W. Wick, M. Weller, C. F. Menck and B. Kaina, Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26, 186-197 (2007).
41. 2 phase. Oncogene 22, 2110-2120 (2003).
42. S. M. Holt, J. L. Scemama, M. I. Panayiotidis and A. G. Georgakilas, Compromised repair of clustered DNA damage in the human acute lymphoblastic leukemia MSH2-deficient NALM-6 cells. Mutat. Res. 674, 123-130 (2009).
43. G. M. Li, Mechanisms and functions of DNA mismatch repair. Cell Res. 18, 85-98 (2008).
44. J. C. Boyer, A. Umar, J. I. Risinger, J. R. Lipford, M. Kane, S. Yin, J. C. Barrett, R. D. Kolodner and T. A. Kunkel, Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res. 55, 6063-6070 (1995).